Clinical Features and Prognostic Analysis of MuSK-Antibody-Positive Myasthenia Gravis versus Double-Seropositive Myasthenia Gravis: A Single-Center Study from Central South China
Ting He,Kangzhi Chen,Yi Li,Zhaohui Luo,Mengchuan Luo,Huan Yang
DOI: https://doi.org/10.2147/ndt.s450651
IF: 2.989
2024-03-30
Neuropsychiatric Disease and Treatment
Abstract:Ting He, 1, &ast Kangzhi Chen, 1, &ast Yi Li, 1 Zhaohui Luo, 1 Mengchuan Luo, 2 Huan Yang 1 1 Department of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China; 2 Department of Geriatrics, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China &astThese authors contributed equally to this work Correspondence: Huan Yang, Department of Neurology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, People's Republic of China, Email Purpose: To decipher the discrepancies between muscle-specific kinase antibody-positive myasthenia gravis (MuSK-MG) and double-seropositive myasthenia gravis (DSP-MG), and to determine prognostic factors for minimal manifestation status (MMS) achievement in MG patients with MuSK autoantibodies (MuSK-Ab). Patients and Methods: A total of 34 MG patients seropositive for MuSK-Ab were enrolled in this study. The demographic and clinical features were compared between MuSK-MG (n = 28) and DSP-MG (n = 6) patients, and factors affecting MMS induction in all patients with MuSK-Ab were identified using Cox regression analysis. Results: Compared to MuSK-MG patients, those with DSP-MG had similar clinical characteristics, except that they had a lower frequency of bulbar muscle involvement at nadir (50% vs 92.9%; P = 0.029) and higher proportions of comorbidities with diabetes mellitus (33.3% vs 0%; P = 0.027) and thymic abnormalities (33.3% vs 0%; P = 0.027). Higher MG Activities of Daily Living (MG-ADL) scores (HR = 0.16, 95% CI: 0.037– 0.7, P = 0.015) and axial muscle involvement at nadir (HR = 0.39, 95% CI: 0.16– 0.94, P = 0.035) were negative prognostic factors for MMS achievement in patients with MuSK-Ab regardless of acetylcholine receptor antibody (AChR-Ab) positivity. Multivariable Cox regression analysis further established higher MG-ADL scores at the nadir (HR = 0.19, 95% CI: 0.04– 0.94; P = 0.042) as an independent risk factor for MMS achievement. Conclusion: DSP-MG was comparable to MuSK-MG and could be considered a single entity in our cohort. In all MG patients with MuSK-Ab, a higher MG-ADL score at nadir may herald a lower chance of MMS achievement, with no observed potential effect of AChR-Ab presence. Keywords: double-seropositive myasthenia gravis, muscle-specific kinase antibody, acetylcholine receptor antibody, minimal manifestation status, myasthenia gravis activities of daily living Myasthenia gravis (MG) is a typical autoimmune disorder involving the dysfunction of acetylcholine signaling at the neuromuscular junction (NMJ) that incurs muscle weakness, where functional autoantibodies directed against nicotinic acetylcholine receptor (AChR), muscle-specific kinase (MuSK), lipoprotein-receptor-related protein 4 (LRP4) and other postsynaptic proteins represent the culprits. 1 Most patients with MG are positive for AChR autoantibodies (AChR-Ab), while MuSK autoantibodies (MuSK-Ab) have been detected in AChR-Ab-seronegative individuals with a wide range of prevalence of 0% to 70% possibly due to the diversity of cohorts and detection methods. 2 MuSK is indispensable for NMJ formation and facilitates AChR clustering in response to nerve-terminal-derived agrin, 3 which binds to LRP4 that forms a heterotetrametric complex with MuSK to enhance the phosphorylation and activation of MuSK. 4 Collagen Q (ColQ), the collagenic tail subunit of acetylcholinesterase (AChE) that regulates AChR clustering, is also anchored via interaction with MuSK. 5 Thus, the presence of MuSK-Ab could interfere with the signaling cascade for neuromuscular transmission and further the normal activity of the nerve-innervated muscle contraction. MuSK-Ab mainly recognize the extracellular Ig-like domains, especially Ig1-2 of MuSK, and the majority of them are of the IgG4 subclass with myasthenogenic activity. 6–8 In contrast to dominance of IgG1 and IgG3 subclasses in AChR-MG that mediate pathogenic effects via complement activation, antigenic modulation and direct blockade of AChR, the IgG4 subclass of MuSK-Ab seems to play roles greatly by disrupting the interactions among the postsynaptic proteins. 9 Intriguingly, MuSK-IgG4 may undergo Fab arm exchange, a unique process that endows the autoantibody with bispecific Fab fragments and functional monovalency, which was demonstrated to exacerbate the pathogenicity of MuSK-Ab. 10,11 In addition, MuSK-Ab are more likely to be produced by short-lived plasmablasts (SLPB) whereas AChR-Ab stem largely from long-lived plasma cells (LLPC). 9 As a consequence, the dis -Abstract Truncated-
psychiatry,clinical neurology